This site uses cookies, including third-party cookies, that help us to provide and improve our services.

Privacy Policy
- Global Locations -
Headquarters
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive, Suite 401, Newark, Delaware - 19713, United States
T: +1-845-579-5705
MEA
Market Access DMCC
1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
Americas
Future Market Insights
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989,
United States
T: +1-347-918-3531
Europe
Future Market Insights
3rd Floor, 207 Regent Street,
London W1B 3HH
United Kingdom
T: + 44 (0) 20 8123 9659
D: +44 (0) 20 3287 4268
APAC
Future Market Insights
Office No. 401-A, 4th Floor,
VANTAGE 9, S.No. 36/1/1,
Baner, Pune 411045 India

EPO Biomarkers Market

Market Insights on EPO Biomarkers covering sales outlook, demand forecast & up-to-date key trends

EPO Biomarkers Market: Global Industry Analysis and Opportunity Assessment 2016-2026

EPO Biomarkers Market: Global Industry Analysis and Opportunity Assessment 2016-2026 Overview

Erythropoietin is special type of protein biomarker, also known as a growth factor. It acts by the stimulating the bone marrow to manufacture red blood cells. There are five different types of erythropoietin biomarkers such as epoetin alfa, epoetin beta, epoetin zeta, epoetin theta and darbepoetin alfa. 

Erythropoietin is mostly administered subcutaneously as an alternative to iron supplements. Erythropoietin used in human beings is also known as recombinant human erythropoietin (rHuEPO). Commercially available rHuEPO has the same 165 amino acid sequence as available in naturally occurring hormone but the level of glycosylation in rHuEPO depends on the testing method used.

Growing global incidence of renal diseases and cancers is expected to create a marked increase in use of EPO biomarkers.

EPO Biomarkers Market: Drivers & Restraints

The prime drivers for the market include growing incidence of cancers and renal diseases. Changes in lifestyle and improper eating habits contribute to pancreatic and endocrine cancers, which often lead to severe anaemia, where external erythropoietin infusion is required. Other drivers for the EPO biomarker market is technological advancement in devising proprietary testing methods apart from tried and tested ones.

Restraints for the market include lack of availability of skilled labour and sufficient quality controlled testing laboratories in most countries in less developed regions. Insufficient R&D in identification of biomarkers due to adoption of cost cutting measures in European regions is expected to restrain proper quantitative assessment of drugs and their therapeutic efficacy in blood.

This could also hamper progress of ongoing clinical trials and proper stratification of patients.

Customize this Report

Let us know your requirement to get
100% FREE customization

EPO Biomarkers Market: Overview

EPO biomarker market is account to rise in value during the forecast period. Due to expansion in the product segment of EPO biomarkers the market share will be rising with a promising rate, also with the increase in demand for diagnosis and treatment of widely spread chronic disease the EPO market is expected to grow with a promising CAGR during the forecast period.

Biologic drug industry is investing on R&D and the key players are focusing on increasing their production capacity for EPO biomarkers. 

EPO Biomarkers Market: Region-wise Outlook

Considering all potential geographic regions, EPO biomarkers market is segmented into seven key regions: North America, Latin America, Eastern Europe, Western Europe, Japan, Asia Pacific and Middle East & Africa.

North America is been dominating in the EPO biomarkers due to rise in acceptance for bio-similar weakly followed by Western and Eastern Europe, Asia Pacific has a dominating presence in EPO biomarker market and most of the key players are locally producing the EPO biomarkers, that is enhancing their market share and product reach. There is a   good opportunity for Japan in EPO biomarker market.

The emerging regions in Asia Pacific, Middle East and Africa holds promising future for rise in EPO biomarker market, due to increase in awareness towards the chronic disease and increase in population simultaneously.

Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

EPO Biomarkers Market: Key Player

Shandong Kexing Bioproducts Co., Ltd., Amgen Inc., Ranbaxy Laboratories Ltd, Johnson & Johnson, Roche Holding AG, Sigma-Aldrich, Thermo Fisher Scientific, Hospira Inc., Biocon, Teva Pharmaceutical Industries Ltd.,

The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also contains projections using a suitable set of assumptions and methodologies. The research report provides analysis and information according to categories such as market segments, geographies, types, technology and applications.

The report covers exhaustive analysis on

  • Market Segments
  • Market Dynamics
  • Market Size
  • Supply & Demand
  • Current Trends/Issues/Challenges
  • Competition & Companies involved
  • Technology
  • Value Chain
Become a MarketNgage Insider

An unified Market Research Subscription Platform, built for today’s disparate research needs.

Regional analysis includes

  • North America (U.S., Canada)
  • Latin America (Mexico, Brazil)
  • Western Europe (Germany, Italy, U.K, Spain, France, Rest of Western Europe)
  • Eastern Europe (Russia)
  • Asia Pacific (China, India, ASEAN, Australia & New Zealand)
  • Japan
  • Middle East and Africa (GCC, S. Africa)

The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

EPO Biomarkers Market: Segmentation

EPO Biomarkers is classified on the basis of biomarker, indication, testing method and end user type:

Based on biomarker type, the global EPO Biomarkers is segmented into the following:

  • Recombinant human erythropoietin
  • Erythropoietin alfa
  • Erythropoietin beta
  • Erythropoietin zeta
  • Erythropoietin theta
  • Darbepoietin alfa

Based on indication, the global EPO Biomarkers is segmented into following:

  • End stage renal disorder
  • Cancers
  • Rheumatoid arthritis
  • AIDS
  • Others

Based on end users, the global EPO Biomarkers is segmented into the following:

  • Diagnostic centers
  • Hospitals
  • Ambulatory care and surgical centers

Table of Content

NA

Customize this Report

Let us know your requirement to get
100% FREE customization

List of Tables

NA

Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

List of Charts

NA

Need specific information?

Request Customization

Explore Healthcare Insights

View Reports
Google translate